| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 2588 | 2015 |
| Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II … ME Taplin, B Montgomery, CJ Logothetis, GJ Bubley, JP Richie, BL Dalkin, ... Journal of clinical oncology 32 (33), 3705, 2014 | 255 | 2014 |
| Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors EJ Chen, AG Sowalsky, S Gao, C Cai, O Voznesensky, R Schaefer, ... Clinical cancer research 21 (6), 1273-1280, 2015 | 191 | 2015 |
| SOX9 drives WNT pathway activation in prostate cancer F Ma, H Ye, HH He, SJ Gerrin, S Chen, BA Tanenbaum, C Cai, ... The Journal of clinical investigation 126 (5), 1745-1758, 2016 | 166 | 2016 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 138 | 2021 |
| Molecular genetics of testicular germ cell tumors Y Sheikine, E Genega, J Melamed, P Lee, VE Reuter, H Ye American journal of cancer research 2 (2), 153, 2012 | 130 | 2012 |
| Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity A Patnaik, KD Swanson, E Csizmadia, A Solanki, N Landon-Brace, ... Cancer Discovery 7 (7), 750-765, 2017 | 127 | 2017 |
| Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma TL Lotan, H Ye, J Melamed, XR Wu, IM Shih, JI Epstein The American journal of surgical pathology 33 (7), 1037-1041, 2009 | 123 | 2009 |
| Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone RR McKay, H Ye, W Xie, R Lis, C Calagua, Z Zhang, QD Trinh, SL Chang, ... Journal of Clinical Oncology 37 (11), 923, 2019 | 103 | 2019 |
| Clonal progression of prostate cancers from Gleason grade 3 to grade 4 AG Sowalsky, H Ye, GJ Bubley, SP Balk Cancer research 73 (3), 1050-1055, 2013 | 102 | 2013 |
| A multi-resolution model for histopathology image classification and localization with multiple instance learning J Li, W Li, A Sisk, H Ye, WD Wallace, W Speier, CW Arnold Computers in biology and medicine 131, 104253, 2021 | 98 | 2021 |
| Decrease in stromal androgen receptor associates with androgen‐independent disease and promotes prostate cancer cell proliferation and invasion Y Li, CX Li, H Ye, F Chen, J Melamed, Y Peng, J Liu, Z Wang, HC Tsou, ... Journal of cellular and molecular medicine 12 (6b), 2790-2798, 2008 | 94 | 2008 |
| Expression of PD-L1 in hormone-naïve and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide C Calagua, J Russo, Y Sun, R Schaefer, R Lis, Z Zhang, K Mahoney, ... Clinical Cancer Research 23 (22), 6812-6822, 2017 | 90 | 2017 |
| Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas J Zavadil, H Ye, Z Liu, JJ Wu, P Lee, E Hernando, P Soteropoulos, ... PloS one 5 (8), e12362, 2010 | 90 | 2010 |
| Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post–World Health Organization/International Society of Urological Pathology … H Miyamoto, F Brimo, L Schultz, H Ye, JS Miller, DA Fajardo, TK Lee, ... Archives of pathology & laboratory medicine 134 (8), 1160-1163, 2010 | 85 | 2010 |
| Difficult differential diagnoses in testicular pathology H Ye, TM Ulbright Archives of pathology & laboratory medicine 136 (4), 435-446, 2012 | 70 | 2012 |
| Low abundance of circulating tumor DNA in localized prostate cancer ST Hennigan, SY Trostel, NT Terrigino, OS Voznesensky, RJ Schaefer, ... JCO precision oncology 3, 2019 | 68 | 2019 |
| Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations AG Sowalsky, H Ye, M Bhasin, EM Van Allen, M Loda, RT Lis, ... Cancer research 78 (16), 4716-4730, 2018 | 61 | 2018 |
| Oligomerization is required for HIV-1 Nef-induced activation of the Src family protein-tyrosine kinase, Hck H Ye, HJ Choi, J Poe, TE Smithgall Biochemistry 43 (50), 15775-15784, 2004 | 59 | 2004 |
| Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy S Wilkinson, H Ye, F Karzai, SA Harmon, NT Terrigino, DJ VanderWeele, ... European urology 80 (6), 746-757, 2021 | 53 | 2021 |
